Oncology ASCO 2026: Are radiopharmaceuticals being systematically und... The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.
Oncology Dose optimisation in oncology: Insights from AACR 2026 and i... Five years after its launch, the FDA’s Project Optimus remained a key theme in discussions at AACR 2026.
News Vogenx surpasses expectations with $81M IPO With $81.3 million raised, Vogenx is the latest in a staggering summer of biotech IPOs. But the queue past this point looks thin.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.